For instance, erlotinib, which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), can be used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer [17], which are the leading causes of cancer-related mortality in the United States [18]. This evidence concerns the gene EGFR and pancreatic neoplasm.